Drug intelligence / Profile preview

bergenin

Development stage
Phase 4
Modality
Small Molecules
Administration
Oral
01

Overview

Bergenin is a naturally occurring C-glycoside of 4-O-methyl gallic acid, classified as a trihydroxybenzoic acid glycoside. It is found in several plant species, including *Bergenia ciliata*, *Bergenia ligulata*, and others. Traditionally used in Ayurvedic, Chinese, and Unani medicine systems, bergenin exhibits a wide range of biological activities. Its mechanisms include potent immunomodulatory effects and antioxidant activity through free radical scavenging. Pharmacologically, it demonstrates anti-inflammatory (via cyclooxygenase-2 inhibition and modulation of Th1/Th2 cytokine production), hepatoprotective, neuroprotective, gastroprotective, antidiabetic (including pancreatic β-cell regeneration), antilithiatic (anti-kidney stone), antifungal (broad-spectrum against filamentous fungi and yeast), antiviral (notably anti-HIV), antimalarial (Plasmodium falciparum inhibition in vitro/in vivo), antimicrobial (excluding bacteria), antinociceptive, and anti-lipid peroxidation properties[1][3][5]. Structure–activity studies also suggest inhibitory action on β-secretase (BACE1)[3].

Other names
cuscutinardisic acid BYanbaicaisuBergeninum
02

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on bergenin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bergenin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call